Spurious hypercreatininemia: 28 neonatal foals (2000-2008)

ECEIM consensus statement on equine kidney disease

The aim of this consensus statement is to summarize and appraise scientific evidence and combine this with the clinical experience of a panel of experts to optimize recommendations on how to recognize and manage kidney disease in horses.

Urinary Tract Disorders of Foals

Urinary disease in the neonatal period can occur with primary congenital renal defects or as a secondary consequence of birth trauma, ischemic injury, nephrotoxic medications, or systemic illness. This article reviews the clinical evaluation of the urinary system in foals and highlights diagnostic and therapeutic features of the most commonly encountered urinary disorders of the equine neonatal patient.

Symmetric dimethylarginine concentrations in healthy neonatal foals and mares

BACKGROUND

Symmetric dimethylarginine (SDMA) is a renal biomarker correlated with glomerular filtration rate (GFR).

OBJECTIVES

Describe changes in SDMA in clinically healthy foals and their mares during the first month postfoaling.

ANIMALS

Convenience sampling of healthy periparturient Thoroughbred mares and their full-term foals from a population of client-owned horses.

METHODS

Serum and EDTA whole blood samples were collected from mares in their last month of pregnancy and then from mares and foals at approximately <12 hours, 48 hours, 7 days, and 30 days postbirth. Samples were processed at a commercial reference laboratory for CBC and serum biochemistry, including SDMA concentrations.

RESULTS

A total of 125 foals and 104 mares were included. Upper limits for SDMA concentrations in foals were above the adult horse reference interval for the first 20 or more days of life. Median SDMA concentrations decreased from 70 μg/dL (range, 7-100 μg/dL) to 18 μg/dL (range, 6-27 μg/dL) during the first 3 to 4 weeks of life. At birth, the SDMA concentration reference range was established as 0 to 100 μg/dL (upper limit of the assay); 0 to 85 μg/dL for 1 to 4 days old, 0 to 36 μg/dL for 5 to 10 days old, and 0 to 24 μg/dL for 20 to 30 days old. The upper reference limits for SDMA concentrations in mares did not differ from the general reference interval for adult horses. No correlation was identified between mare and foal SDMA concentrations (ρ = .06, P = .58).

CONCLUSIONS AND CLINICAL IMPORTANCE

Foal SDMA concentrations remained higher than the upper limit of the adult reference range and foals require a different reference range dependent on age.

Serum symmetric dimethylarginine concentration in healthy neonatal Thoroughbred foals

BACKGROUND

Symmetric dimethylarginine (SDMA) is widely used in other species as a marker of renal dysfunction and is considered a more sensitive indicator of glomerular filtration rate than creatinine. Reference ranges are established in healthy adult horses (≤14 μg/dL) and concentrations are increased in horses with acute kidney injury (median 32 μg/dL; range 15-92).

OBJECTIVES

To establish the normal range of SDMA concentrations in neonatal Thoroughbreds.

STUDY DESIGN

Cross-sectional.

METHODS

Blood samples were collected from Thoroughbred foals <36 h old deemed healthy by physical examination. Exclusion criteria included foals from mares undergoing treatment for placentitis and foals that developed clinical disease or died/euthanised <2 weeks from birth. Biochemistry and serum SDMA concentrations were obtained.

RESULTS

Subjects included 120 foals. Median age was 13.5 h (range 1.0-34.0). Median and 95% confidence interval for SDMA concentration was 69.0 µg/dL (63.0, 75.0; range 35.0-376.0). A cut-off value of 168 µg/dL would include 95% of individuals and is therefore suggested. Serum SDMA concentration was correlated with age (R = -.3, P = .003), creatinine concentration (R = .6, P ≤ .001) and urea concentration (R = .3, P = .002).

MAIN LIMITATIONS

Limitations include a small sample size, no consideration of subclinical disease and a short follow-up period.

CONCLUSIONS

In equine neonates, SDMA concentration is higher than in adult horses, older foals and adults with acute kidney injury. Therefore, currently SDMA cannot be used as a marker of renal dysfunction in this age group. Further work is required to assess whether SDMA concentration is increased in neonates with renal disease and, if so, what cut-off should be used.

Symmetric dimethylarginine and renal function analysis in horses with dehydration

BACKGROUND

Acute dehydration caused by a variety of diseases in horses can lead to acute kidney injury. However, current renal biomarkers usually indicate renal damage late in the course of the disease. A novel biomarker would be helpful to diagnose renal disease earlier.

OBJECTIVES

(1) To estimate the correlation of serum symmetric dimethylarginine (SDMA) concentrations with the degree of dehydration, traditional renal biomarkers and renal function analysis, and (2) to determine the value of SDMA as a prognostic and early biomarker of renal injury in horses.

STUDY DESIGN

Prospective cohort.

METHODS

Serum SDMA, creatinine and urea concentrations and renal function analysis were measured in 41 horses with dehydration at 4 time points until 48 h after admission. Horses were grouped according to their dehydration level into mildly, moderately and severely dehydrated groups.

RESULTS

Serum SDMA concentrations at admission correlated with creatinine concentrations (r = .412, P < .001). Differences in SDMA concentrations at admission were detected among dehydration levels but not between survivors and nonsurvivors. Significant correlations of SDMA concentrations with other markers of renal function analysis and short-term outcome were not observed.

MAIN LIMITATIONS

Besides the small sample size and low statistical power, missing urine samples at specific time points were also 1 of the main limitations. Only 1 of the horses developed acute kidney injury, which made the evaluation of the predictive value of SDMA difficult.

CONCLUSIONS

SDMA concentrations correlated significantly with creatinine concentrations in dehydrated horses. Further research is needed to reveal the application of SDMA in horse.

NEONATAL INTENSIVE CARE OF 10 HOSPITALIZED GIRAFFE CALVES (GIRAFFA CAMELOPARDALIS) REQUIRING HAND-REARING

This retrospective case series describes the clinicopathologic findings, diagnoses, treatment, and outcomes of 10 hand-reared newborn giraffe (Giraffa camelopardalis) calves admitted to a university teaching hospital for intensive care. Ten calves (five males, five females; nine reticulated giraffes [Giraffa camelopardalis reticulata], one Masai giraffe [G. c. tippelskirchi]), were admitted under 2 days of age. Inadequate transfer of passive immunity was suspected in 5 of 10 calves based on assessment of serum total solids and globulin values. These calves were treated with oral frozen bovine colostrum and/or intravenous hyperimmune bovine plasma. Diarrhea occurred in 6 of 10 calves and was managed with supportive care, fecal microbiota transplantation, and limiting milk intake (offering 10% body weight [BW] in milk per day, while feeding <2 L per meal at 2- to 4-hr intervals). Less common diagnoses included pneumonia (n = 3) and mycoplasma-associated septic arthritis (n = 1). Eight calves received systemic antimicrobial therapy. Hyperlactatemia (lactate > 5 mmol/L; n = 8) and hypercreatininemia (creatinine > 2.0 mg/dl, n = 7) were the most common presenting laboratory abnormalities, which resolved with intravenous fluid therapy. All neonatal giraffes survived to discharge after a median hospitalization of 9.5 days (range, 5-37 days) and were successfully hand-reared at their place of birth. In conclusion, neonatal giraffe calves can be intensively managed in a hospital environment. Diarrhea was a common clinical problem and can be related to feeding regimens. Intravenous hyperimmune bovine plasma infusion was well tolerated to manage failure of transfer of passive immunity in calves with inadequate colostrum administration. The current study supports that compromised neonatal giraffe calves may carry an excellent prognosis after early, intensive intervention.

Serum symmetric dimethylarginine concentration in healthy horses and horses with acute kidney injury

BACKGROUND

There are limited options to diagnose acute kidney injury (AKI) in horses. Symmetric dimethylarginine (SDMA) is routinely used in human and small animal medicine. The aim of this study was to assess serum SDMA concentrations in healthy horses and horses with AKI. The objective of this study was to evaluate the association of: 1) age, 2) sex, 3) body weight and 4) serum creatinine and urea levels on serum SDMA concentrations. Fifty-three healthy horses, including 17 foals (2-6 months of age) and 36 adult horses (3-29 years of age), and 23 horses with AKI were included in the study based on history, physical examination, blood analysis, urinalysis and an ultrasonographic examination of the urinary tract. Serum SDMA concentrations were measured using a non-species specific commercial ELISA test.

RESULTS

In healthy adult horses, the value of SDMA was 0.53 ± 0.14 μmol/L. The value was higher in foals (1.5 ± 0.4 μmol/L, P < 0.001). Horses with AKI had significantly higher concentrations of SDMA compared to healthy horses (1.76 ± 1.05 μmol/L, P < 0.001). In the healthy adult horses, there was no association of sex, age or body weight on SDMA. However, a significant positive relationship was found between serum creatinine and SDMA concentrations.

CONCLUSIONS

Healthy adult horses had SDMA values similar to those of other species. Foals had higher SDMA values. Therefore, different reference values should be created for them. The study confirmed an increased SDMA in horses with AKI. This, as well as the low influence of extrarenal factors on the SDMA values, may confirm its usefulness in the diagnosis of kidney dysfunction. Higher SDMA values may also indicate a more advanced degree of kidney dysfunction. Further research is required to determine whether SDMA could be used to detect kidney dysfunction in the asymptomatic stage of AKI.

The Sick Adult Horse: Renal Clinical Pathologic Testing and Urinalysis

Clinicopathologic evaluation of renal function and renal disease in sick adult horses remains grounded in detection of azotemia, assessment of serum and urine electrolyte concentrations, and evaluation of urinalysis findings, including specific gravity, reagent strip analysis, and sediment examination. Because increases in serum or plasma urea nitrogen and creatinine concentrations are insensitive indicators of a decreased glomerular filtration rate, there is considerable interest in identifying novel biomarkers of renal function or injury in blood and urine, with serum symmetric dimethylarginine concentration being the most recent addition to the commercial market.

Prevalence of acute kidney injury in a population of hospitalized horses

BACKGROUND

Hospital-acquired acute kidney injury (AKI) in humans and dogs increases morbidity and nonsurvival. Azotemia at presentation has been associated with a poor outcome in horses; however, prevalence and consequences of hospital-acquired AKI are unreported.

HYPOTHESIS/OBJECTIVES

To evaluate the prevalence of AKI in hospitalized horses, risk factors associated with AKI, and the effect of AKI on short-term survival. We hypothesized that the prevalence of AKI in horses is similar to that reported in other domestic mammalian species and would be associated with nonsurvival.

ANIMALS

Adult horses hospitalized for >2 days from which a minimum of 2 measurements of serum creatinine concentration were available.

METHODS

Retrospective cohort study. Clinical records were reviewed and horses grouped according to their baseline serum creatinine concentration and change in serum creatinine concentration from baseline. The associations between signalment, diagnosis, and treatment variables, and the presence of azotemia or AKI were assessed using multinomial logistic regression. The relationship between these conditions and survival to discharge was evaluated.

RESULTS

Three hundred twenty-five horses were included; 4.3% (14/325) had azotemia at baseline and 14.8% (48/325) developed AKI. There were no significant associations between investigated risk factors and development of AKI. The presence of azotemia and AKI did not significantly affect survival to discharge (P = .08 and .81, respectively).

CONCLUSIONS AND CLINICAL IMPORTANCE

The prevalence of AKI in this population of hospitalized horses is similar to that reported in dogs and humans; however, in this study population, there was less impact on morbidity and short-term survival.

The clinical value of whole blood point-of-care biomarkers in large animal emergency and critical care medicine

OBJECTIVE

To summarize the current medical literature and provide a clinical perspective of whole blood point-of-care (POC) biomarkers in large animal emergency and critical care practice.

DATA SOURCES

Original studies, reviews, and textbook chapters in the human and veterinary medical fields.

SUMMARY

POC biomarkers are tests used to monitor normal or disease processes at or near the patient. In both human and veterinary medicine these tools are playing an increasingly important role in the management of critical diseases. The most important whole blood POC biomarkers available for veterinary practitioners include l-lactate, cardiac troponin I, serum amyloid A, triglyceride, creatinine, and glucose, although many other tests are available or on the horizon.

CONCLUSION

Whole blood POC biomarkers enable clinicians to provide improved management of critical diseases in large animals. These tools are especially useful for establishing a diagnosis, guiding therapy, and estimating disease risk and prognosis.

The equine neonatal intensive care laboratory: point-of-care testing

Rapid evaluation and intervention is a requirement and a characteristic of patient management in neonatal intensive care units, and this applies for equine neonates also. Appropriate interventions are based on solid knowledge of age, maturity, and species-specific differences in reference ranges. Point-of-care (POC) testing devices speedup decision making regarding treatments and interventions. However, there are potential limitations of these devices when applied to age groups and species beyond those they were specifically developed for. This article discusses the age-specific differences in the reference ranges and the potential limitations of POC devices currently used, which may affect delivery of care.